Gut microbiota and the paradox of cancer immunotherapy

Frontiers in Immunology

Volumn 5, Issue APR, 2014, Pages

  Poutahidis, Theofilos ^a,b   Kleinewietfeld, Markus ^a,c,d   Erdman, Susan E ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Cancer immunotherapy; Inflammation and cancer; Probiotic bacteria; Regulatory T cells; Tumor macroenvironment

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; INTESTINE FLORA; MUTAGENESIS; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT;

EID: 84900841740     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00157     Document Type: Article

References (59)

1. Stewart BW, Wild CP editors. World Cancer Report 2014. Lyon: Cedex (2014).
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell (2000) 100:57-70. doi:10.1016/S0092-8674(00)81683-9.
3. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer (2001) 1:46-54. doi:10.1038/35094059.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013.
5. Erdman S, Poutahidis T. Roles for inflammation and regulatory T cells in colon cancer. Toxicol Pathol (2010) 38:76-87. doi:10.1177/0192623309354110.
6. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 21:309-22. doi:10.1016/j.ccr.2012.02.022.
7. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet (2001) 357:539-45. doi:10.1016/S0140-6736(00)04046-0.
8. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature (2004) 431:405-6. doi:10.1038/431405a.
9. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer (2004) 4:540-50. doi:10.1038/nrc1388.
10. Erdman SE, Poutahidis T. Cancer inflammation and regulatory T cells. Int J Cancer (2010) 127:768-79. doi:10.1002/ijc.25430.
11. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis (2009) 30:1073-81. doi:10.1093/carcin/bgp127.
12. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol (2008) 20:241-6. doi:10.1016/j.coi.2008.04.008.
13. Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol (2012) 22:327-34. doi:10.1016/j.semcancer.2012.03.004.
14. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. Regulatory T cells in cancer. Adv Cancer Res (2010) 107:57-117. doi:10.1016/S0065-230X(10)07003-X.
15. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer (2007) 7:880-7. doi:10.1038/nrc2250.
16. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol (2014) 27C:1-7. doi:10.1016/j.coi.2013.12.005.
17. Gajewski TF, Fuertes MB, Woo SR. Innate immune sensing of cancer: clues from an identified role for type I IFNs. Cancer Immunol Immunother (2012) 61:1343-7. doi:10.1007/s00262-012-1305-6.
18. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell (2008) 133:775-87. doi:10.1016/j.cell.2008.05.009.
19. +CD25+ regulatory T cells at the single-cell level. Eur J Immunol (2005) 35:1681-91. doi:10.1002/eji.200526189.
20. Gavin MA, Torgerson TR, Houston E, Deroos P, Ho WY, Stray-Pedersen A, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A (2006) 103:6659-64. doi:10.1073/pnas.0509484103.
21. + T cells expressing the FoxP3 transcription factor. Immunity (2009) 30:899-911. doi:10.1016/j.immuni.2009.03.019.
22. Kleinewietfeld M, Hafler DA. The plasticity of human Treg and Th17 cells and its role in autoimmunity. Semin Immunol (2013) 25:305-12. doi:10.1016/j.smim.2013.10.009.
23. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 10:942-9. doi:10.1038/nm1093.
24. Hodi FS. Overcoming immunological tolerance to melanoma: targeting CTLA-4. Asia Pac J Clin Oncol (2010) 6(Suppl 1):S16-23. doi:10.1111/j.1743-7563.2010.01271.x.
25. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 105:3005-10. doi:10.1073/pnas.0712237105.
26. +ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A (2008) 105:14987-92. doi:10.1073/pnas.0806075105.
27. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and Gm-Csf combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 116:1935-45. doi:10.1172/JCI27745.
28. + T cells in a dose-dependent fashion. Blood (2008) 112:1175-83. doi:10.1182/blood-2007-11-125435.
29. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 364:2119-27. doi:10.1056/NEJMoa1012863.
30. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol (2009) 27:186-92. doi:10.1200/JCO.2008.18.7229.
31. Badoual C, Hans S, Fridman WH, Brasnu D, Erdman S, Tartour E. Revisiting the prognostic value of regulatory T cells in patients with cancer. J Clin Oncol (2009) 27:e5-6. Author reply e7.
32. Whiteside TL. Disarming suppressor cells to improve immunotherapy. Cancer Immunol Immunother (2012) 61:283-8. doi:10.1007/s00262-011-1171-7.
33. Leffers N, Gooden MJ, De Jong RA, Hoogeboom BN, Ten Hoor KA, Hollema H, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother (2009) 58:449-59. doi:10.1007/s00262-008-0583-5.
34. Wilke CM, Wu K, Zhao E, Wang G, Zou W. Prognostic significance of regulatory T cells in tumor. Int J Cancer (2010) 127:748-58. doi:10.1002/ijc.25464.
35. + CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am J Pathol (2003) 162:691-702. doi:10.1016/S0002-9440(10)63863-1.
36. +)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res (2003) 63:6042-50.
37. +CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res (2005) 65:3998-4004. doi:10.1158/0008-5472.CAN-04-3104.
38. Rao VP, Poutahidis T, Ge Z, Nambiar PR, Boussahmain C, Wang YY, et al. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res (2006) 66:7395-400. doi:10.1158/0008-5472.CAN-06-0558.
39. Poutahidis T, Haigis KM, Rao VP, Nambiar PR, Taylor CL, Ge Z, et al. Rapid reversal of interleukin-6-dependent epithelial invasion in a mouse model of microbially induced colon carcinoma. Carcinogenesis (2007) 28:2614-23. doi:10.1093/carcin/bgm180.
40. + lymphocytes modulate prostate cancer progression in mice. Int J Cancer (2009) 125:868-78. doi:10.1002/ijc.24452.
41. Erdman SE, Rao VP, Olipitz W, Taylor CL, Jackson EA, Levkovich T, et al. Unifying roles for regulatory T cells and inflammation in cancer. Int J Cancer (2010) 126:1651-65. doi:10.1002/ijc.24923.
42. Poutahidis T, Kleinewietfeld M, Smillie C, Levkovich T, Perrotta A, Bhela S, et al. Microbial reprogramming inhibits western diet-associated obesity. PLoS One (2013) 8:e68596. doi:10.1371/journal.pone.0068596.
43. Rao VP, Poutahidis T, Fox JG, Erdman SE. Breast cancer: should gastrointestinal bacteria be on our radar screen? Cancer Res (2007) 67:847-50. doi:10.1158/0008-5472.CAN-06-3468.
44. Erdman SE, Rao VP, Poutahidis T, Rogers AB, Taylor CL, Jackson EA, et al. Nitric oxide and TNF-alpha trigger colonic inflammation and carcinogenesis in Helicobacter hepaticus-infected, Rag2-deficient mice. Proc Natl Acad Sci U S A (2009) 106:1027-32. doi:10.1073/pnas.0812347106.
45. Lakritz JR, Poutahidis T, Levkovich T, Varian BJ, Ibrahim YM, Chatzigiagkos A, et al. Beneficial bacteria stimulate host immune cells to counteract dietary and genetic predisposition to mammary cancer in mice. Int J Cancer (2013). doi:10.1002/ijc.28702.
46. + CD45RB(hi) lymphocytes promote mammary and intestinal carcinogenesis in Apc(Min/+) mice. Cancer Res (2006) 66:57-61. doi:10.1158/0008-5472.CAN-05-3445.
47. Poutahidis T, Cappelle K, Levkovich T, Lee CW, Doulberis M, Ge Z, et al. Pathogenic intestinal bacteria enhance prostate cancer development via systemic activation of immune cells in mice. PLoS One (2013) 8:e73933. doi:10.1371/journal.pone.0073933.
48. Houghton J, Li H, Fan X, Liu Y, Liu JH, Rao VP, et al. Mutations in bone marrow-derived stromal stem cells unmask latent malignancy. Stem Cells Dev (2010) 19:1153-66. doi:10.1089/scd.2009.0439.
49. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology (2010) 138(2101-2114):e5. doi:10.1053/j.gastro.2010.01.058.
50. Zhu Y, Michelle Luo T, Jobin C, Young HA. Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett (2011) 309:119-27. doi:10.1016/j.canlet.2011.06.004.
51. Arthur JC, Perez-Chanona E, Muhlbauer M, Tomkovich S, Uronis JM, Fan TJ, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science (2012) 338:120-3. doi:10.1126/science.1224820.
52. Song X, Gao H, Lin Y, Yao Y, Zhu S, Wang J, et al. Alterations in the microbiota drive interleukin-17C production from intestinal epithelial cells to promote tumorigenesis. Immunity (2014) 40:140-52. doi:10.1016/j.immuni.2013.11.018.
53. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 342:967-70. doi:10.1126/science.1240527.
54. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 342:971-6. doi:10.1126/science.1240537.
55. Rook GA, Dalgleish A. Infection, immunoregulation, and cancer. Immunol Rev (2011) 240:141-59. doi:10.1111/j.1600-065X.2010.00987.x.
56. Folkman J, Kalluri R. Cancer without disease. Nature (2004) 427:787. doi:10.1038/427787a.
57. Poutahidis T, Kearney SM, Levkovich T, Qi P, Varian BJ, Lakritz JR, et al. Microbial symbionts accelerate wound healing via the neuropeptide hormone oxytocin. PLoS One (2013) 8:e78898. doi:10.1371/journal.pone.0078898.
58. Levkovich T, Poutahidis T, Smillie C, Varian BJ, Ibrahim YM, Lakritz JR, et al. Probiotic bacteria induce a 'glow of health.' PLoS One (2013) 8:e53867. doi:10.1371/journal.pone.0053867.
59. Poutahidis T, Erdman S. Probiotic "glow of health": more than skin deep. Benef Microbes (2014) 5:109-19. doi:10.3920/BM2013.0042.